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Summary
P21ras proteins are thought to play an important role in cell proliferation and differentiation.
Single nucleotide mutations in the encoding cellular proto-oncogenes often result in p2lras proteins
with transforming activity. Such activated ras oncogenes have been demonstrated in a variety
of human malignancies and also in preneoplastic changes. Using a synthetic peptide corresponding
to amino acids 5-16 of mutated p2lras proteins with an exchange ofthe normal glycine at position
12 by valine, it is shown here that human CD4+ T cells specifically recognize the mutated
protein sequence and can be generated as antigen-specific T lymphocyte lines. The fact that these
T lines did not crossreact to the sequence of normal p2lras proteins offers new perspectives for
specific immunotherapy of human malignancies and even precancerous lesions.
T
he family of human ras proto-oncogenes (1) encodes
membrane-bound proteins (p2lras), which are thought
to be involved in signal transduction across the cell mem-
brane. In this function, they most probably play a role in
the regulation of cell growth and differentiation. Mutations
in ras genes, which lead to proteins with increased activity,
can be the molecular basisfor the development of cancer. Single
nucleotide mutations, which mainly occur in the codons 12,
13, and 61 of the ras proto-oncogenes, have been shown to
result in malignant transformation ofthe cell (2, 3) . Ras gene
mutations have been identified in a variety of human cancers
(4-7). The demonstration of tumor-specific protein sequences
in human malignancies raises the question as to whether the
immune system is able to recognize and to distinguish them
from the normal protein .
Therefore, we analyzed the cellular immune response to
a synthetic peptide (peptide 12va1) representing amino acids
5-16 of mutated p2lras proteins with an exchange of the
normal glycine at position 12 by valine. This peptide was
chosen because in this region the products of the human Ha-
ras, Ki-ras, and N-rasproto-oncogenes show identical amino
acid sequences and because the substitution of glycine by va-
line induces transforming activity (2, 3) and is one of the
most commonly found p2lras mutations in human tumors.
Materials and Methods
Antigens.
￿
Synthetic peptides representing amino acids 5-16 of
normal p2lras proteins and the oncogene-encoded p2lras protein
had the sequences KLVVVGAGGVGK (peptide 12gly) and KLV
VVGAVGVGK (peptide 12va1), respectively. Peptides were prepared
by Multiple Peptide Systems (San Diego, CA). PHA (Sigma Chem-
ical Co., St. Louis, MO) was used in a concentration of2.5 pg/ml.
Primary Responses and Generation of T Cell Lines. T lympho-
cyte lines specific for peptide 12va1 were established from periph-
eral blood samples of healthy individuals using a microculture ap-
proach. PBL were isolated from EDTA blood by centrifugation on
Lymphoprep(Nygaard, Oslo, Norway) gradients. Washed PBL were
resuspended in RPMI 1640 (Gibco Laboratories, Eggenstein, FRG)
containing 1 mM glutamine (Gibco Laboratories), 1% MEM nones-
sential amino acids (100x) (Gibco laboratories), 100 U/ml peni-
cillin, 100 p,g/ml streptomycin (Biochrom, Berlin, FRG), and 2%
heat-inactivated FCS (Gibco Laboratories), referred to as complete
medium. 2 x 10' cells in a volume of 100 pl/well were seeded
into 96-well flat-bottomed microtiter plates (Nunc, Roskilde, Den-
mark). The peptide 12va1 was added to primary cultures in a final
concentration of 10 /4g/ml and cultures were incubated at 5%
COZ. Assays of the primary immune response were labeled after
4 d with 0.2 uCi fH]methyl-thymidine (Amersham, Braunschweig,
FRG) per well and harvested 18 h later. At this time, cultures set
up for the generation of T lines were provided with 100 ul/well
of complete medium containing 15 U/ml human 11,2 (Lymphocult-
HP; Biotest Diagnostics, Frankfurt, FRG) and 10% FCS. In in-
tervals of3-4 d, cultures were provided with fresh 11,2 containing
medium without splitting.
Primary cultures were restimulated for the first time on day 16-18
by the split-well procedure. Cells were washed twice within their
wellswith 100 141 RPMI 1640. Cellsofeach well were resuspended
in 100 ul complete medium, and twice, 50 p.l of cell suspension
from each well was transferred into two adjacent wells of a new
microtiterplate. Only one of the two wells was provided with pep-
tide 12va1, but in both wells, 1.2 x 10' irradiated (4,000 rad) au-
tologous PBL were seeded in a volume of50 j,1 complete medium.
3 d later, cell growth in two adjacent wells derived from one single
well was compared microscopically, and cultures with antigen-
273
￿
J. Exp. Med. ® The Rockefeller University Press - 0022-1007/91/01/0273/04 $2.00
Volume 173 January 1991 273-276specific cell proliferation were provided with IL2-containingmedium
for further propagation . Exchange of 11,2 medium was again per-
formed every third or fourth day and, when necessary, cultures were
split .
In intervals of 14-16 d, cells were restimulated as described for
proliferation assays . 72 h later, complete medium was replaced by
IL2-containing medium .
Proliferation Assays.
￿
3 x 10" peptide 12va1-generated T line
cells were activated with 1.2 x 105 irradiated autologous PBL in
the absence or presence of antigens or mitogen in a final volume
of120 /Al . Cultures were labeled during the second day of restimu-
lation with 0.2 liCi ['H]methyl-thymidine (Amersham) per well
and harvested 18 h later onto glass fiber filters by a cell harvester
(Skatron, Inc., Sterling, VA) . ['H]Methyl-thymidine incorporation
was measured by liquid scintillation counting . Data from triplicate
cultures are given as arithmetic means .
Transfectants.
￿
Murine HLADRl-transfected fibroblasts (LDRI)
as APC were kindly provided byJ . Trowsdale, London . The trans-
fectants were kept in RPMI containing 10% FCS and 1 mg
Hygromycin B/ml (Sigma Chemical Co ., St . Louis, MO) . For
proliferation assays, trypsinized and washed fibroblasts were in-
cubated for 1 h at 37°C in RPMI containing mitomycin C (100
,ug/ml) (Sigma Chemical Co .) . Fibroblasts were washed three times
and seeded at a density of 5 x 10" cells per well.
Antibodies.
￿
mAbs to monomorphic determinants of the human
HLA-DP, -DQ, and -DR molecule were obtained from Becton
Dickinson & Co . (Mountain View, CA) . Before use, antibodies
were dialyzed in PBS to remove sodium azide. 10 td of antibody
solution was added per well .
Results and Discussion
Existence ofPeptide 12val-reactive T Lymphocytes in Normal
Individuals . Immune responses to peptide 12va1 were ana-
lyzed in primary cultures of freshly isolatedPBL derived from
healthy persons. None of the four individuals investigated
showed a significant primary response to the mutated pro-
tein sequence. In spite ofthis, T cell lines specific for peptide
12va1 could be established from thePBL of two healthy indi-
viduals . Maximal T line activation was induced by peptide
12val concentrations in a range from 0.3 to 30 hg peptide/ml
(Fig . 1) . These T cell lines, though derived from different
donors, showed similar dose responses .
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Figure 1.
￿
Activation ofT cell line JA-12 by peptide 12va1 but not by
peptide 12gly. [3H]Thymidine incorporation of peptide 12val-specific T
cells restimulated with irradiated autologous PBL in the absence or pres-
ence ofindicated concentrations of peptide 12val (*) or peptide 12gly (0) .
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Peptide 12val-speck T Cells Are Not Autoreactive .
￿
Anal-
ysis of the T line responses to a second peptide (peptide 12gly),
which represents the corresponding amino acids of unmu-
tated p2lras proteins, revealed that none of the lines recog-
nizing the sequence of the mutated protein (peptide 12va1)
crossreacted to the sequences ofnormal p2lras proteins (pep-
tide 12gly) (Fig . 1) .
Results of peptide competition experiments using subop-
timal concentrations of peptide 12va1 (0.1 hg/ml) and pep-
tide 12gly concentrations up to 100 p,g/ml suggested that
nonactivation of peptide 12val-specific lines is caused by non-
presentation of peptide 12gly by APC (not shown) .
Peptide 12val-specific T Cells Are CD4' andMHC Class
II Restricted. Antigen-induced proliferation of the peptide
12va1 line HZ.2, derived from a HLA-DR1 homozygous
donor, could be blocked by antibodies directed toHLA-DR ;
the HLADR1 restriction of the line was further substan-
tiated by presentation of peptide 12va1 by HLA-DR1-
transfected fibroblasts (Fig. 2) .
The phenotype of the peptide 12va1-specific T lines was
analyzed by cytofluorometry . All five lines investigated were
composed ofCD3+ CD4+ CD8- T cells bearing TCRa/0
(data not shown) .
This study demonstrates that theimmune system ofnormal
individuals contains CD4+ T lymphocytes specifically recog-
nizing a protein sequence associated with malignant or pre-
neoplastic cell transformation, and that it is possible to prop-
agate these T lymphocytes in vitro using a peptide that
corresponds to the highly conserved region of p2lras pro-
teins with an oncogenic point mutation at position 12 .
The fact that none of the T lines is activated by the se-
quence of the normal proto-oncogene product, thus are not
autoreactive, offers new perspectives for specific immuno-
therapy ofhuman neoplasms : either for adoptive immuno-
therapy with in vitro generated peptide 12va1-specific autol-
ogousT cells or for active immunization with peptide 12val .
Usage of peptides for the generation ofT cell populations
specific for oncogene-transformed cells may include the op-
portunity to generate cytotoxic MHC class II-restricted
Figure 2.
￿
HLA-DRI restriction of the peptide 12va1-specific T cell line
HZ .2 . [3H]Thymidine incorporation of peptide 12val-specific T cells re-
stimulated with autologous PBL (leftsetofcolumns) orHLADR1-transfected
murine fibroblasts (LDR1) (second set of columns) .CD4+ T cells (8), as well as class I-restricted CD8+ T lym-
phocytes (9-11); both cell types, at leastin part (9), have been
shown to be able to lyse also cells producing the recognized
epitope endogenously (8, 10, 11). Also since proteins that
are in their native state not expressed on the surface of the
cell membrane canbe recognized by T lymphocytes (12-14),
oncogene-encoded protein sequencesbecome attractive targets
for immunotherapy (15).
In the murine and human system, the establishment of
tumor-specific T cell lines has been described (16, 17), and
it was shown that thesepopulations, although of the CD4+
phenotype, confer tumor-specific immunity (18, 19) and
mediate eradication of established tumors (20, 21). The im-
portant role of CD4+ lymphocytes in tumor immunity is
further confirmed by in situ studies of the tumor environ-
ment (22).
T cells specific forras oncogene-encoded proteins mayhave
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advantages in contrast to tumor-specific populations men-
tioned above, which aremainly reactive to tumor-specific trans-
plantation antigens (TSTA) (17). A unique TSTA is only
presenton tumorcellsderived from asingle tumor, or a single
cell, thus are individual for a certain tumor, in contrast to
the sequence of mutated ras proteins, which occur in tumor
cells ofcompletely different origin. In addition, loss ofTSTA-
encoding genes by the tumor cells is a general feature and
results, concerning this antigen, in nonimmunogenic tumor
cells, which then can spread rapidly in the host (23). This
cannot occur in oncogene-driven tumor cells since loss of
themutatedoncogene would result in loss of tumorigenicity.
In addition, T cells specific for thesequence ofmutated p2lras
proteinwould also be able to attack transformed cellsin precan-
cerous lesions, which have been shown to contain ras on-
cogene mutations as well (5, 24, 25).
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